U.S., April 11 -- ClinicalTrials.gov registry received information related to the study (NCT06922448) titled 'Study of BLU-808 in Allergic Rhinoconjunctivitis' on April 03.
Brief Summary: This study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of BLU-808 in participants with ragweed (Ambrosia artemisiifolia)-induced allergic rhinoconjunctivitis (ARC). Participants will undergo eligibility assessments that include exposure to ragweed pollen in an allergen exposure chamber (AEC).
Study Start Date: April, 2025
Study Type: INTERVENTIONAL
Condition:
Allergic Rhinoconjunctivitis
Intervention:
DRUG: BLU-808
BLU-808 tablets
DRUG: Placebo
Placebo tablets
Recruitmen...